Professor Binder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The randomized, investigator-initiated FOCUS trial has completed enrollment of 75 patients with recurrent or metastatic head and neck squamous cell...

European governments are beginning to take an interest in techniques to link scant evidence, as the euphoria about the benefits of mega datasets wanes

Media Credit: Grace Hromin | Senior Photo Editor Charnovitz, who received accolades from colleagues upon his departure last month, said he’s seen the senate lose some of its value to the University during the past year. News By Isha Trivedi May 10, 2021 12:25 AM Former Faculty Senate Parliamentarian Steve Charnovitz said his final senate meeting late last month was a “depressing” end to his 13-year stint in the position. Charnovitz, who started teaching at GW in 2004, has held the position of senate parliamentarian longer than anyone else in the senate’s history. As his tenure has...

Study ) Phase II trial is an investigator-sponsored, randomized Phase II clinical trial that will recruit patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma across 10 clinical sites in Germany. The trial will evaluate the addition of UV1 to a standard of care treatment with PD-1 checkpoint inhibitor pembrolizumab as compared to pembrolizumab monotherapy. A total of 75 patients indicated for treatment with pembrolizumab will be enrolled in the FOCUS study, randomized 2-to-1 so that 50 patients will receive UV1 and pembrolizumab and 25 patients will recei...

Study ) Phase II trial is an investigator-sponsored, randomized Phase II clinical trial that will recruit patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma across 10 clinical sites in Germany. The trial will evaluate the addition of UV1 to a standard of care treatment with PD-1 checkpoint inhibitor pembrolizumab as compared to pembrolizumab monotherapy. A total of 75 patients indicated for treatment with pembrolizumab will be enrolled in the FOCUS study, randomized 2-to-1 so that 50 patients will receive UV1 and pembrolizumab and 25 patients will recei...